Develops esophageal cancer diagnostic tests for patients with gastroesophageal reflux disease.
Jun 2026Revenue $112K/yrExpenses $26.8M/yr
No trendCash runway ≈ 6 months from Jun 2026
Figures by year
When will PAVmed be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Jun 2026, revenue was $112K and expenses $26.8M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $71.0K | $21.9M | −$21.8M |
| Dec 2024 | $3.00M | $47.5M | −$44.5M |
| Dec 2023 | $2.45M | $71.2M | −$68.8M |
| Dec 2022 | $377K | $91.5M | −$91.1M |
| Dec 2021 | $500K | $54.9M | −$54.4M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.